"Discount Likely to Be Resolved
on the Back of Bioepis Growth"

On June 17, Samsung Securities initiated coverage on Samsung Epis Holdings with a "Buy" investment rating and a target price of 600,000 won.


Keunhee Seo, a research analyst at Samsung Securities, stated, "Samsung Bioepis has secured stable cash flow based on solid biosimilar sales growth," adding, "Mid- to long-term re-rating is expected through the expansion of next-generation biosimilars and new drug platforms."


[Click e-Stock] "Samsung Epis Holdings Likely to Be Revalued as a Platform Holding Company" View original image

Currently, Samsung Epis Holdings is trading in an undervalued range, but it is expected that this discount can be resolved in the future. Seo explained, "While a certain level of holding company discount relative to net asset value (NAV) is inevitable due to its holding company structure, compared to competitors such as Celltrion, which receives high multiples thanks to its vertically integrated biosimilar development, manufacturing, and sales structure, Samsung Epis Holdings is undervalued due to the holding company discount and supply-demand uncertainties. However, this discount could be resolved as Samsung Bioepis expands its portfolio and the value of its new drugs is reevaluated."


Seo summarized the current sluggish stock price as "a result of structural factors and a lack of pipeline visibility." He said, "The amortization expenses from PPA associated with the acquisition of Samsung Bioepis have been reflected, making PER-based valuation less meaningful, and since the new drug pipeline is still in its early stages, the story of transitioning into a new drug company is not yet fully reflected in the stock price."



Seo also projected that Samsung Bioepis, the core subsidiary of Samsung Epis Holdings, will continue to increase its market share in the US and Europe through a stable biosimilar portfolio, and that with new product launches, the company will enter a high-growth phase over the next three to five years. He concluded, "The conditions to escape the current discount are being gradually met," and added, "Samsung Epis Holdings is likely to be re-evaluated as a global bio platform holding company centered on Samsung Bioepis, rather than just as a biosimilar company."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing